Syndax Pharmaceuticals (NasdaqGS:SNDX) Earnings Call Presentation

FDA Approval of Revuforj® (revumenib) in R/R NPM1 Mutated AML October 24, 2025 2 Agenda for today's call Opening Remarks & Key Highlights Michael Metzger, Chief Executive Officer 2 Revuforj (revumenib) Label & Supporting Data Dr. Nick Botwood, Head of R&D and Chief Medical Officer 3 Delivering Revuforj to Patients Steve Closter, Chief Commercial Officer Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform A ...